SUBSCRIBE
SUBSCRIBE
News   Drug Development

Capstone Therapeutics Announces Initiation of Dosing for AZX100 Phase 2 Clinical Trial in Dermal Scarring; Management to Host Teleconference and Webcast Today

February 10, 2009 | 
1 min read
TEMPE, Ariz., Feb. 10, 2009 (GLOBE NEWSWIRE) -- Capstone Therapeutics (Nasdaq:CAPS) announced today the initiation of dosing for its AZX100 Phase 2 clinical trial in dermal scarring.
Clinical research Phase II
MORE ON THIS TOPIC
Stagflation, economic slow down or recession while inflation high up, GDP growth decrease causing by unemployment concept, fearful businessman riding fall down economic graph with inflation high up.
Immunology and inflammation
Vyne Crashes After Safety Signal in Dogs Puts Hold on Clinical Trial of Plaque Psoriasis
April 25, 2025
 · 
2 min read
 · 
Tristan Manalac
IN PARTNERSHIP WITH DIA
Economic Challenges, Strategic Investments: Reshaping the Women’s Health Landscape
April 24, 2025
 · 
1 min read
 · 
Lori Ellis
Two boxing gloves give a fist bump on a colored background. Collage art
Lung cancer
Summit’s Bispecific Beats Yet Another Cancer Med, Pressuring Keytruda’s ‘Supremacy’
April 23, 2025
 · 
2 min read
 · 
Tristan Manalac
Pictured: Bristol Myers Squibb office in California
Neuropsychiatric disorders
‘Strike 2?’ BMS Stumbles Again as Cobenfy Disappoints in Schizophrenia
April 23, 2025
 · 
2 min read
 · 
Tristan Manalac